Given thealready successful use of anti-TNF biologics in the treatment of rheumatoid arthritis, inflammatorybowel disease and psoriasis, it is not unreasonable to think that CNS delivery of such agents mayafford therapeutic benefit to patients with PD or other neurological disorders characterized bychronic neuroinflammation (Clark et al., 2010). The gene discussed is TNF; the disease is Parkinson disease.